Organic Active Ingredients TRIZ Cases

Guaijaverin protects retinal cells from blue-light optical damage by reducing oxidative stress, inflammation, and apoptosis.

A modified-release oral minoxidil formulation smooths PK peaks to support hair regrowth while lowering adverse effects from immediate release.

Timed-release levodopa mini-tablets delay dosing until the small intestine, improving absorption predictability and morning akinesia control.

Henna-derived compounds inhibit Malassezia growth while helping address dandruff and scalp conditions with less disruption to scalp microbiome balance.

A modular RNA sensor targets Gfral-expressing area postrema neurons to modulate IL-6 signaling for cachexia and obesity therapy.

Selective biased KOR agonists reduce CNS penetration to relieve pain and hyperalgesia without sedation or neuromuscular incoordination.

Targeted siRNA or ASO inhibition of MS4A4E lowers liver fat, fibrosis, and NAFLD activity while improving metabolic markers.

Oxalic acid cocrystal forms improve stability and solubility of this kinase inhibitor while easing solid-form selection for drug development.

A poloxamer and elastin-collagen hydrogel stays injectable at room temperature, gels at body temperature, and releases drugs for up to 7 days.

Structural changes to camptothecin ADC payloads improve tumor-cell inhibition, plasma stability, targeting, and safety.

Folic acid-modified liposome-coated tilianin nanocrystals improve solubility, mucus penetration, and oral bioavailability for atherosclerosis therapy.

Using HPMC-AS solid dispersions, rifaximin delays refractory ascites and reduces hospitalization time in cirrhosis complications.

Hydrolyzable lipidoid LNPs improve liver nucleic acid delivery, endosomal escape, and tolerated dosing while reducing toxicity.

Selective bicyclic NNMT inhibitors target cancer-associated fibroblasts to reduce tumor burden while minimizing toxicity to normal tissues.

A six-amino-acid formulation speeds fluid absorption and supports tight junction integrity when gastric emptying and intestinal uptake limit hydration.

XRPD and thermal analysis distinguish Cot inhibitor solid forms, enabling reliable selection and quality control for therapeutic use.

Hydrophilic rosmarinic acid derivatives self-assemble into microparticles that improve solubility, bioavailability, and anti-inflammatory delivery.

Single-stranded oligonucleotides degrade MLH3 mRNA to curb trinucleotide repeat expansion and slow related neurodegenerative disorders.

A pyrazolopyrimidine scaffold with tailored 3- and 5-substituents expands Trk kinase inhibition across cancers and related diseases.

Sequential two-step mixing separates core nucleation from stabilization to achieve up to 95% nanoparticle loading with stable sub-100 nm particles.

An abluminal-only antiproliferative coating separates drug delivery from degradation control to lower thrombosis and restenosis risk.

A polysiloxane or polyisobutylene patch matrix enables once-daily asenapine delivery with improved bioavailability and low skin irritation.

A cotinine-linked CAR T platform enables retargeting across antigens and selective CAR T cell removal to curb immunotoxicity.

Multiple steaming and maturation enrich black ginseng extract with Rk1 and Rg5 to inhibit influenza while reducing resistance and side effects.

Chiral backbone and sugar modifications improve oligonucleotide stability, uptake, and splicing activity while reducing toxicity and complement activation.

Selective P2X3 antagonists reduce afferent neuron sensitivity to relieve endometriosis pain with fewer side effects and less recurrence.

A spherical eye-contact support and guided needle angles improve ciliary muscle electroporation while reducing injury risk.

A Formula I inhibitor boosts USP28/USP25 inhibition while limiting structural complexity, helping destabilize c-MYC and LSD1 in tumors.

Novel Formula I compounds tune heteroaromatic substituents to inhibit SSAO and support treatment of inflammation, fibrosis, diabetes, stroke, and cancer.

Direct lung delivery of inhaled ivermectin achieves therapeutic pulmonary concentrations while avoiding the safety limits of higher oral dosing.

Small molecule pyrazinotriazines inhibit CBP/β-catenin signaling to address inadequate Wnt pathway therapies for cancer, fibrosis, and diabetes.

Novel SSTR4 agonist salts improve excipient stability plus flow and bulk properties, supporting reliable pharmaceutical manufacturing and pain treatment.

A defined inulin DP profile lowers sinusitis risk, improves immune performance, and stays well tolerated over 6 months.

IV brincidofovir formulations use lyophilized or aqueous compositions to maintain antiviral exposure while reducing intestinal toxicity.

PEG-ended carbonate apatite particles improve lesion accumulation while reducing liver and other normal organ uptake for safer drug delivery.

Specific JAK inhibitor crystal forms improve solubility and thermal stability while enabling selective JAK1/TYK2 inhibition with better safety.

Nonapoptotic Formula A compounds trigger methuosis or autophagy to kill apoptosis-resistant cancer cells and improve drug sensitivity.

Small molecule receptor modulators improve glucose metabolism and weight control while avoiding the administration complexity of peptide therapies.

Glycomimetic fucose analogs selectively block FTVI and FTVII to suppress sLex formation while preserving Lewis X production.

Negatively charged polysaccharides are blended with RG-I pectin before heat-drying to limit aggregation and improve solubility.

Combining a CDK4/6 inhibitor with a KRAS G12C inhibitor helps overcome intrinsic resistance and improve potency across lung cancer cell lines.

Freezing CO2-rich amine solutions creates carbonic acid adducts with improved storage stability, enabling advance pharmaceutical preparation.

Selective 3CL protease inhibitors block SARS-CoV-2 replication while enabling oral, inhalation, and intranasal COVID-19 treatment.

Novel GPX4-targeting senolytic compounds improve solubility and oral bioavailability while selectively clearing senescent cells.

SBEβCD inclusion complexing with bicarbonate improves meloxicam solubility and bioavailability for faster oral absorption and pain relief.

Selective CBP/EP300 bromodomain inhibitors improve therapeutic efficacy while limiting off-target effects by modulating acetylation-driven transcription.

An in vitro pDC activation assay identifies gastric-tolerant lactic acid bacteria that induce interferon for antiviral prophylaxis.

Structural changes in 2-aminopyrimidine TLR8 modulators improve activity, selectivity, safety, and pharmacokinetics for immune-related diseases.

Combining targeted B-cell therapy with IL-6 modulation and optional CXCR4 inhibition helps lower IgM, reduce resistance, and improve apoptosis.

Crystallizing eribulin salts through diacid and low molecular weight amine complexation improves purity, stability, and moisture resistance.